Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is assessment of glycemic control and physicians satisfaction with results of DM2 OAD monotherapy
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Patients have an established diagnosis of T2D, Age 35 years and more, Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To assess levels of compensation of T2D by HbA1c levels in patients on OAD monotherapy | 1 visit within 4 month | |
| To assess frequency of target levels of HbA1c ≤ 7% in patients with T2D during OAD monotherapy | 1 visit within 4 month |
| Measure | Description | Time Frame |
|---|---|---|
| To assess fasting glycemia in patients with T2D on OAD monotherapy | 1 visit within 4 month | |
| To assess postprandial levels of glycemia in patients with T2D during OAD monotherapy | 1 visit within 4 month |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Clinical practice
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alexey Stepanov | AstraZeneca | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Arkhangelsk | Russia | ||||
| Research Site |
Not provided
Not provided
Not provided
Not provided
| To evaluate the physicians' satisfaction with the results of OAD monotherapy in patients with Typ 2 Diabetes (T2D) | 1 visit within 4 month |
| To compare the results of OAD monotherapy in different groups of patients | 1 visit within 4 month |
| Astrakhan |
| Russia |
| Research Site | Barnaul | Russia |
| Research Site | Chelyabinsk | Russia |
| Research Site | Izhevsk | Russia |
| Research Site | Kazan' | Russia |
| Research Site | Khemerovo | Russia |
| Research Site | Kirov | Russia |
| Research Site | Kurgan | Russia |
| Research Site | Moscow | Russia |
| Research Site | Nizhny Novgorod | Russia |
| Research Site | Perm | Russia |
| Research Site | Petrozavodsk | Russia |
| Research Site | Rostov-on-Don | Russia |
| Research Site | Samara | Russia |
| Research Site | Seversk | Russia |
| Research Site | Smolensk | Russia |
| Research Site | St-Peterburg | Russia |
| Research Site | Tomsk | Russia |
| Research Site | Tyumen | Russia |
| Research Site | Ufa | Russia |
| Research Site | Yaroslavl | Russia |
| Research Site | Yoshkar-Ola | Russia |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided